The Efficacy and Adverse Reactions of Neotetracycline in the Treatment of GNB Infections
- Conditions
- Infections With Drug-resistant Gram-negative Bacteria
- First Posted Date
- 2025-05-25
- Last Posted Date
- 2025-05-25
- Target Recruit Count
- 300
- Registration Number
- NCT06990126
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Nimotuzumab Plus Definite Chemoradiotherapy(dCRT) in Elderly Patients With Esophageal Squamous Cell Carcinoma
Phase 2
Recruiting
- Conditions
- Esophageal Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2025-05-25
- Last Posted Date
- 2025-05-25
- Target Recruit Count
- 95
- Registration Number
- NCT06988956
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
Rapid Detection of Pseudomonas Aeruginosa in Bronchoalveolar Lavage Fluid Using Label-free Single-particle Imaging Technology and Assessment of Post-treatment Efficacy in Patients With Pseudomonas Aeruginosa Infection
Not yet recruiting
- Conditions
- Rapid DetectionPseudomonas Aeruginosa Infection
- First Posted Date
- 2025-05-23
- Last Posted Date
- 2025-06-27
- Target Recruit Count
- 100
- Registration Number
- NCT06986512
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
PERformance of Multi-Cancer Early-detectIon Based on Various Biomarkers in fEmale BREAST Cancers, PERCEIVE-BREAST
Active, not recruiting
- Conditions
- Cancer
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-05-20
- Target Recruit Count
- 496
- Registration Number
- NCT06979921
- Locations
- 🇨🇳
Jiangsu Provincial People's Hospital, Nanjing, Jiangsu, China
🇨🇳The Affiliated Hospital of Medical College Qingdao University, Qingdao, Shandong, China
A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC
Phase 2
Not yet recruiting
- Conditions
- NSCLC (Non-small Cell Lung Cancer)Neoadjuvant ImmunotherapyAdjuvant Immunotherapy
- Interventions
- Drug: tislelizumab in combination with anlotinib and platinum-based doublet chemotherapy
- First Posted Date
- 2025-05-18
- Last Posted Date
- 2025-06-29
- Target Recruit Count
- 40
- Registration Number
- NCT06977828
- Locations
- 🇨🇳
The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Venetoclax as Consolidation in CLL Patients Treated With BTK Inhibitor Monotherapy
Phase 2
Recruiting
- Conditions
- Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
- Interventions
- Drug: Venetoclax combined with IbrutinibDrug: Venetoclax combined with ZanubrutinibDrug: Venetoclax combined with AcalabrutinibDrug: Venetoclax combined with Orelabrutinib
- First Posted Date
- 2025-05-06
- Last Posted Date
- 2025-05-06
- Target Recruit Count
- 79
- Registration Number
- NCT06958705
- Locations
- 🇨🇳
Department of Haematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu, China
A Study Comparing of P-GEMD Regimen Versus P-Gemox Regimen With Untreated Early-Stage NUAT or Advanced-Stage ENKTL.
Phase 3
Not yet recruiting
- Conditions
- NK-T-Cell Lymphoma, Extranodal
- Interventions
- Drug: P-GEMDDrug: P-Gemox
- First Posted Date
- 2025-05-01
- Last Posted Date
- 2025-05-01
- Target Recruit Count
- 60
- Registration Number
- NCT06953739
Using ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer
Phase 3
Active, not recruiting
- Conditions
- Gastric Cancer Stage III
- Interventions
- Drug: Tislelizumab + SOX ChemotherapyDrug: SOX Chemotherapy
- First Posted Date
- 2025-04-22
- Last Posted Date
- 2025-07-01
- Target Recruit Count
- 416
- Registration Number
- NCT06939439
- Locations
- 🇨🇳
First Affiliated Hospital with Nanjing Medical Unviersity, Nanjing, Jiangsu, China
VA Dual Sequential Therapy
Phase 4
Recruiting
- Conditions
- Helicobacter Pylori Infection
- Interventions
- Drug: Vonoprazan and Amoxicillin for the first 7 daysDrug: Vonoprazan and Amoxicillin for the first 5 daysDrug: Vonoprazan and Amoxicillin for 14 daysDrug: Vonoprazan and Amoxicillin for the second 7 daysDrug: Vonoprazan and Amoxicillin for the second 5 days
- First Posted Date
- 2025-04-16
- Last Posted Date
- 2025-05-20
- Target Recruit Count
- 600
- Registration Number
- NCT06929962
- Locations
- 🇨🇳
The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China
Circumferential Pulmonary Vein Isolation Plus Transition Zone Modification in Atrial Fibrillation Patients Without Low-Voltage Areas
Not Applicable
Not yet recruiting
- Conditions
- Atrial Fibrillation (AF)
- First Posted Date
- 2025-04-16
- Last Posted Date
- 2025-04-16
- Target Recruit Count
- 162
- Registration Number
- NCT06930599